Aurobindo Pharma (AUROPHARMA) — Corporate Action

📢 Key Event
Incorporation of Avogent Lifesciences Private Limited as wholly owned subsidiary

💡 Investor Takeaway
The subsidiary enables direct manufacturing operations in India and foreign markets without immediate financial outlay.

Aurobindo Pharma announced incorporation of Avogent Lifesciences Private Limited, a wholly owned subsidiary, to expand manufacturing and marketing operations in India and abroad. The new entity was incorporated on August 31, 2026 with an initial paid-up capital of Rs. 5,000,000 divided into 500,000 equity shares of Rs.10 each. It operates as a related party transaction under SEBI LODR regulations. The subsidiary has no prior turnover history and requires no regulatory approvals for establishment.

📄 View Original Announcement (PDF)

📊 Stock Analysis — AUROPHARMA ✨ Ask AI About This

About Aurobindo Pharma Ltd (AUROPHARMA)

Healthcare · Pharmaceuticals · Listed on BSE

Market Cap: ₹94,419.51 Cr P/E: 25.6 ROE: 9.8% ROCE: 12.8% Div Yield: 0.24%

View full AUROPHARMA stock details →

📡 Get AI alerts when AUROPHARMA files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track AUROPHARMA — Free

💡 Ask AI about this filing

"What is the planned timeline for operational launch of Avogent?" "How will the subsidiary impact Aurobindo's consolidated financials?" "What specific markets outside India will Avogent target first?"

Ask AI Free →

📊 More AUROPHARMA filings

See all AUROPHARMA filings →

🔥 Also filed on 1 September 2026

BCONCEPTS Brand Concepts Ltd Annual Report RAMANEWS Shree Rama Newsprint Ltd Annual Report 544083 Shree Marutinandan Tubes Ltd Annual Report MSTCLTD MSTC Ltd Annual Report CORDSCABLE Cords Cable Industries Ltd Annual Report SHERVANI Shervani Industrial Syndicate Ltd Corporate Action

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when AUROPHARMA files new disclosures

Track AUROPHARMA filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track AUROPHARMA — Free

Free account · 2 AI queries/day

About · Privacy Policy · Terms of Service · Pricing

Today's Announcements · Screener · Insights · AI Chat

Data provided by CMOTS Internet Technologies Pvt Ltd